The physiological effects of glucocorticoids (GCs) are, at least in part, mediated by inhibition of cell proliferation. Two isozymes of 11b-hydroxysteroid dehydrogenase (11b-HSD) interconvert cortisol (F) and inactive cortisone (E), and are thus able to modulate GC action at an autocrine level. Previously, we have demonstrated absent expression of 11b-HSD2 in normal pituitaries; however, in a small number of pituitary tumors analysed, 11b-HSD2 was readily demonstrable. Here we have used realtime RT-PCR to quantify expression of mRNA for 11 b-HSD1 and 2 in 105 human pituitary tumors and have performed enzyme expression and activity studies in primary pituitary cultures. Overall, pituitary tumors expressed lower levels of 11b-HSDl mRNA compared with normals (0.2-fold, Po0.05). In contrast, expression of 11b-HSD2 mRNA was 9.8-fold greater in tumors than in normals (Po0.001). Enzyme assays showed significant 11b-HSD2 activity (71.9722.3 pmol/h/mg protein (mean7s.d.)) but no detectable 11b-HSDl activity. Proliferation assays showed that addition of glycyrrhetinic acid (an 11b-HSD2 inhibitor) resulted in a 30.377.7% inhibition of cell proliferation. In summary, we describe a switch in expression from 11b-HSDl to 11b-HSD2 in neoplastic pituitary tissue. We propose that abnormal expression of 11b-HSD2 acts as a proproliferative prereceptor determinant of pituitary cell growth, and may provide a novel target for future tumor therapy.
The physiological effects of glucocorticoids (GCs) are, at least in part, mediated by inhibition of cell proliferation. Two isozymes of 11b-hydroxysteroid dehydrogenase (11b-HSD) interconvert cortisol (F) and inactive cortisone (E), and are thus able to modulate GC action at an autocrine level. Previously, we have demonstrated absent expression of 11b-HSD2 in normal pituitaries; however, in a small number of pituitary tumors analysed, 11b-HSD2 was readily demonstrable. Here we have used realtime RT-PCR to quantify expression of mRNA for 11 b-HSD1 and 2 in 105 human pituitary tumors and have performed enzyme expression and activity studies in primary pituitary cultures. Overall, pituitary tumors expressed lower levels of 11b-HSDl mRNA compared with normals (0.2-fold, Po0.05). In contrast, expression of 11b-HSD2 mRNA was 9.8-fold greater in tumors than in normals (Po0.001). Enzyme assays showed significant 11b-HSD2 activity (71.9722.3 pmol/h/mg protein (mean7s.d.)) but no detectable 11b-HSDl activity. Proliferation assays showed that addition of glycyrrhetinic acid (an 11b-HSD2 inhibitor) resulted in a 30.377.7% inhibition of cell proliferation. In summary, we describe a switch in expression from 11b-HSDl to 11b-HSD2 in neoplastic pituitary tissue. We propose that abnormal expression of 11b-HSD2 acts as a proproliferative prereceptor determinant of pituitary cell growth, and may provide a novel target for future tumor therapy.
Oncogene ( (Sanchez et al., 1993; Rogatsky et al., 1997) . Although it is now clear that GCs regulate the transcription of a diverse array of target genes, the precise mechanisms by which GR-mediated changes in cell proliferation and differentiation occur are still far from clear. Circulating levels of GCs are sensitively maintained by the hypothalamo-pituitary-adrenal axis during normal physiology. Nevertheless, 'prereceptor' regulatory mechanisms have been described for several steroid hormones that involve target tissue activation or inactivation of the circulating hormone (Labrie et al., 2000) . For GCs, tissue-specific metabolism is catalyzed by two isozymes of 11b-hydroxysteroid dehydrogenase (11b-HSD) (Stewart and Krozowski, 1999 ) that interconvert biologically active cortisol and inactive cortisone. 11b-HSD1 acts predominantly as an oxoreductase in key GC target tissues such as liver, gonads and adipose tissue, converting cortisone to cortisol, thereby regulating the level of active GC available to the intracellular GC receptor (GR). In contrast, 11b-HSD2 is a dehydrogenase enzyme found predominantly in mineralocorticoid responsive tissues such as kidney, salivary gland and colon. In these tissues 11b-HSD2 converts cortisol to cortisone, thereby protecting the mineralocorticoid receptor (MR) from inappropriate occupation by cortisol (White et al., 1997; Stewart and Krozowski, 1999) . Thus the two 11b-HSD isozymes act as critical regulators of GC action at a tissue level, and their contribution to classical endocrine diseases such as apparent mineralocorticoid excess (Stewart et al., 1996) and central obesity (Stewart and Tomlinson, 2002 ) is well established. However, in recent studies we have highlighted a novel role for 11b-HSDl and 2 as autocrine determinants of cell proliferation and differentiation (Rabbitt et al., 2002) . In particular, we have postulated that inappropriate expression of 11b-HSD2 in GR-rich tissues may act as a proproliferative and potentially neoplastic stimulus to cell growth.
Previous studies have documented the expression of 11b-HSD isozymes in both rodent and human pituitarines (Whorwood et al., 1993; Robson et al., 1998; Korbonits et al., 2001) . The function of 11b-HSD in the pituitary has yet to be fully clarified but it seems unlikely to represent an additional level of endocrine regulation within the established hypothalamic-pituitary-adrenal axis (Korbonits et al., 2001 ). More recently, we have observed a marked difference between normal and tumorous pituitaries with respect to 11b-HSD2 expression. 11b-HSD2 protein was undetectable in normal pituitaries but was readily detectable in pituitary tumors. We have therefore carried out further studies to characterize mRNA levels for 11b-HSDl and 2 in a large cohort of normal and neoplastic pituitary tissue. Data confirm a switch in expression from 11b-HSDl to 11b-HSD2 in pituitary tumors, with primary tumor cell cultures demonstrating significant 11b-HSD2 activity. Furthermore, proliferation studies using an 11b-HSD2 inhibitor suggest that abnormal expression of this isozyme may play an important role in determining pituitary tumor growth.
Using real-time RT-PCR we demonstrated both 11b-HSDl and 2 mRNAs in normal pituitary tissue. Overall, pituitary adenomas expressed significantly lower levels of 11b-HSDl mRNA compared with normal pituitary tissue (0.2-fold, Po0.05, Figure 1a ), and this was true for ACTH-, PRL-,TSH-secreting, and nonfunctioning adenomas, but not for GH-secreting adenomas (1.3-fold excess, P ¼ N/S), perhaps reflecting the localization of 11b-HSDl to predominantly somatotropes in the normal pituitary (Korbonits et al., 2001) . In contrast, the expression of 11b-HSD2 mRNA was 9.8-fold (Po0.001) greater in the total group of pituitary tumors than in normal pituitaries (Figure 1b) . ACTH-secreting adenomas had the lowest expression of 11b-HSD2 mRNA within the group of tumors, although greater than in normal pituitaries at 2.5-fold (P ¼ N/S). GHsecreting tumors expressed 8.2-fold excess (Po0.01), PRL-secreting tumors 8.3-fold excess (P ¼ 0.05), and TSH-secreting tumors 3.0-fold excess (P ¼ N/S). The greatest expression of 11b-HSD2 mRNA was observed in NFAs with 12.1-fold excess (Po0.001).
Six pituitary adenomas (four nonfunctioning, two GH-secreting) were maintained in primary culture. RNA extraction and enzyme activity studies were performed on day 3. RT-PCR analyses confirmed the presence of mRNA for 11b-HSD2 but absence for 11b-HSD1 in the primary tumor cultures (Figure 2b) . Likewise, 11b-HSD2 activity (F-E conversion) was readily detectable in all adenomas examined (Figure 2a) , whereas there was no detectable 11b-HSD1 activity in any of the pituitary adenomas analysed. In six tumors (all non-functioning) nuclear incorporation of [ 3 H]thymidine was used to assess proliferation of pituitary tumor cells in the presence or absence of the 11b-HSD2 inhibitor glycyrrhetinic acid (GA, Figure 2c ). Treatment with GA alone for 24 h decreased pituitary cell proliferation by 30.3 77.7% compared to control cells. (**Po0.01), probably because of inhibition of the metabolism of corticosteroids present within the culture medium. GA also potentiated the antiproliferative effects of exogenously added cortisol (***Po0.001), adding further evidence that its actions are mediated, at least in part, by the attenuation of local glucocorticoid inactivation by 11b-HSD2.
In summary, we have observed a marked switch in 11b-HSD isozyme mRNA expression between normal and neoplastic pituitary tissue. 11b-HSDl expression was significantly reduced while 11b-HSD2 expression was increased approximately 10-fold in pituitary tumors compared with normals. Moreover, enzyme conversion data also showed that 11b-HSD activity in pituitary adenomas was exclusively due to the type 2 isozyme. Inhibition of 11b-HSD2 by GA inhibited pituitary cell proliferation and also potentiated the antiproliferative effect of exogenously added cortisol. We propose that a switch in 11b-HSD isozyme expression in the pituitary may confer a growth advantage and thus contribute to the process of pituitary tumorigenesis. Reduced 11b-HSD1 in pituitary tumors is likely to result in attenuated local conversion of cortisone to cortisol. Moreover, significantly increased 11b-HSD2 expression in pituitary tumors will further reduce the availability of biologically active cortisol by enhancing its inactivation to cortisone. Thus the net effect of the observed switch in 11b-HSD isozyme expression in pituitary tumors is to reduce intrapituitary bioavailability of active, antiproliferative GCs. Our preliminary data showing GA-induced inhibition of cell proliferation would support such a concept.
GCs are known to inhibit cell proliferation and induce differentiation. These responses, which have been demonstrated in a variety of tissues, are associated with GC-mediated cell cycle arrest in the G 1 -phase (Rogatsky et al., 1997) . A reduction in GC concentrations locally within the pituitary would thus diminish antiproliferative effects and promote pituitary cell over-proliferation and tumorigenesis. Elevated 11b-HSD2 expression has previously been described in leukemic (Gingras and Margolin, 2000) and breast cancer cell lines (Hundertmark et al., 1997; Koyama et al., 2001) . In the latter, the high oxidative activity of 11b-HSD2 inactivated GCs and thereby abrogated their antiproliferative action. However, addition of an 11b-HSD2 inhibitor blocked GC inactivation and resulted in restoration of the antiproliferative effect, causing a 40-47% decrease in cell proliferation. Studies in primary bone cell cultures have revealed exclusive expression of 11b-HSD1, although in osteosarcoma cell lines, high levels of 11b-HSD2 expression were apparent (Bland et al., 1999; Cooper et al., 2000) . We have recently used stable transfectants of ROS 17/2.8 osteosarcoma cells that express either 11b-HSD1 or 2 to determine effects on cell proliferation (Rabbitt et al., 2002) . We observed a significant reduction in proliferation in 11b-HSDlexpressing cells and a significant increase in proliferation in 11b-HSD2-expressing cells. The latter could be abrogated by the addition of GA or by transfection of a nonfunctional mutant cDNA for 11b-HSD2, demonstrating that the proproliferative effects of 11b-HSD2 were due to increased capacity for the local inactivation of cortisol. The proliferative potential of 11b-HSD2 was further demonstrated by transient transfection studies using non-neoplastic HEK-293 human embryonic kidney cells that showed a 50% increase in proliferation 48 h after transfection with cDNA for 11b-HSD2 (Rabbitt et al., 2002) . Crucially, the potent effects of 11b-HSD1 and 2 on cell proliferation were independent of any change in GR expression, further emphasizing the pivotal role of these isozymes as determinants of cell Figure 1 Pituitary total RNA was extracted utilizing the Sigma Trizol kit and was reverse transcribed using AMV reverse transcriptase (Promega, Madison, WI, USA) as described previously (Gittoes et al., 1997) . Expression of mRNA for the 11b-HSD isozymes was determined using real-time RT-PCR (McTernan et al., 2001) . Probe and primer sequences were as follows -11b-HSDl forward AGGAAAGCTCATGGGAGGACTAG, reverse ATGGTGAATATCATCATGAAAAAGATTC, probe CATGCT-CATTCTCAACCACATCACCAACA; 11b-HSD2 forward GGGCCTATGGAA-CCTCCAA, reverse GACCCACGTTTCTCACT-GACTCT, probe CCGTGGCGCTACTCATGGA-CACA. All reactions were multiplexed with 18S ribosomal RNA. Reactions were as follows: 501C for 2 min, 951C for 10 min; then 44 cycles of 951C for 15 s and 601C for 1 min. (a) Relative levels of expression of 11b-HSD1 mRNA in normal pituitaries and pituitary tumors. Normal pituitaries (Norm) were normalized to 1 and compared to all pituitary tumors collectively (All), nonfunctioning adenomas (NFAs), GH-secreting (GH), ACTH-secreting (ACTH), PRL-secreting (PRL), and TSH-secreting (TSH) pituitary tumors. (b) Relative levels of expression of 11b-HSD2 mRNA in normal pituitaries and pituitary tumors (as identified in A). *Po0.05, **Po0.01, ***Po0.001. Numbers of tumors analysed and absolute levels of mRNA (expressed as mean DCT7s.e.m) are given in tabular form below each figure. Data were analysed using Minitab version 13 software. The Student's T-test was used for group comparisons and this was performed at the DCT stage proliferation. The precise cause of the switch from 11b-HSD1 in normal tissues to 11b-HSD2 in neoplastic equivalents is still unclear. Recent in vivo footprinting studies of the 11b-HSD2 gene promoter have shown distinct upstream regions associated with cell-specific transregulation of this isozyme (Nawrocki et al., 2002) . Similar promoter elements may also be involved in tumor-associated expression of 11b-HSD2, although alternative promoter usage is also possible.
The mechanisms by which GCs regulate cell proliferation are poorly understood. However, among the most prominent GC target genes are the cyclindependent kinases (CDKs) and their corresponding CDK inhibitors (CDIs) (Kato et al., 1994) . Some of these such as the Cip/Kip family of CDIs, particularly p57 kip2 , are rapidly regulated by GCs and are central to the GC-induced accumulation of cells in the G 1 -phase of the cell cycle (Rogatsky et al., 1997; Samuelsson et al., 1999) . Abnormal expression of CDIs has been described in human pituitary tumors (Bamberger et al., 1999; Lidhar et al., 1999) and has also been implicated in the genesis of pituitary tumors in mice (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . Interestingly, mice lacking both p18 and p27
Kipl rapidly develop fatal pituitary adenomas (Franklin et al., 1998) . GCs may also alter cell cycling by modulating growth factor-mediated changes in tyrosine kinase signalling, either by direct effects on membrane receptor expression or by indirect regulation of protein phosphorylation (Croxtall et al., 2000) . Furthermore, GR-mediated transrepression of NF-kB signalling is also important in controlling cell cycle progression (McKay and Cidlowski, 1999) . Thus, a switch in 11b-HSD expression may impact on several signal transduction pathways associated with cell proliferation, and further studies to clarify this mechanism are currently underway within our group.
Our current observations and the supporting data that 11b-HSD2 may have a proproliferative effect in some neoplasms raises the intriguing possibility of novel therapeutic strategies to modulate tumor growth. There have been previous reports of antiproliferative and potent anticancer properties of the liquorice derivatives glycyrrhizin and GA, which are inhibitors of 11b-HSD activity (Shiota et al., 1999; Motoo and Sawabu, 1994) . Clearly, however, the systemic delivery of such an agent would cause unwanted effects in other 11b-HSD2 expressing tissues, for example hypertension due to inhibition of renal 11b-HSD2 (Stewart et al., 1987) . As such, an alternative therapeutic approach may involve targeted gene delivery of vectors encoding 11b-HSD1 in order to reconstitute normal glucocorticoid responsiveness in the pituitary.
Our data have highlighted the role of 11b-HSD2 as a prereceptor regulator of pituitary cell growth, and we have uncovered a novel tumor marker that may help to elucidate fundamental aspects of the pathophysiology of pituitary and also other neoplasms.
